Gyre Therapeutics (GYRE) Capital Expenditures (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Capital Expenditures of $178000.0 for Q1 2026, up 45.9% year-over-year from $122000.0 in Q1 2025, and up 23.61% quarter-over-quarter from $144000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Capital Expenditures (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Capital Expenditures for 15 consecutive years, with $178000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 45.9% year-over-year to $178000.0; the TTM figure through Mar 2026 stood at $1.2 million (down 43.52% YoY), while the FY2025 annual figure was $1.2 million, down 48.6% from the prior year.
- Capital Expenditures rose to $178000.0 in Q1 2026 per GYRE's latest filing, from $144000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.5 million in Q2 2023 and bottomed at -$65000.0 in Q4 2024.
- Historically, Capital Expenditures has averaged $938461.5 across 4 years, with a median of $668000.0 in 2025.
- Annual changes were most pronounced in 2024 — Capital Expenditures sank 102.8% — and 2025, when it surged 321.54%.
- Gyre Therapeutics' Capital Expenditures stood at $2.3 million in 2023, then tumbled by 102.8% to -$65000.0 in 2024, then soared by 321.54% to $144000.0 in 2025, then grew by 23.61% to $178000.0 in 2026.
- Business Quant data shows GYRE's Capital Expenditures at $178000.0 in Q1 2026, $144000.0 in Q4 2025, and $668000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 262,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 262,000.00 |
| Jun 30, 2026 | 262,000.00 |
| Mar 31, 2026 | 178,000.00 |
| Mar 31, 2026 | 178,000.00 |
| Dec 31, 2025 | 144,000.00 |
| Dec 31, 2025 | 144,000.00 |
| Sep 30, 2025 | 668,000.00 |
| Sep 30, 2025 | 668,000.00 |
| Jun 30, 2025 | 256,000.00 |
| Jun 30, 2025 | 256,000.00 |
| Mar 31, 2025 | 122,000.00 |
| Mar 31, 2025 | 122,000.00 |
| Dec 31, 2024 | -65,000.00 |
| Dec 31, 2024 | -65,000.00 |
| Sep 30, 2024 | 693,000.00 |
| Sep 30, 2024 | 693,000.00 |
| Jun 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 1.46 Mn |
| Mar 31, 2024 | 231,000.00 |
| Mar 31, 2024 | 231,000.00 |